You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis

    SBC: Stemsynergy Therapeutic            Topic: 102

    DESCRIPTION provided by applicant The tumor suppressor Adenomatous Polyposis Coli APC directs degradation of catenin a central signaling protein in the WNT pathway Germline loss of function mutations in APC activate WNT signaling and underlie the inherited colorectal cancer predisposition syndrome Familial Adenomatous Polyposis FAP an orphan disease while somatic mutations lead to spo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Novel immunotherapy strategy for treatment of pancreatic cancer

    SBC: Oncotab, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Pancreatic cancer has the worst prognosis of all cancers and is the fourth leading cause of cancer related deaths in the United States Patients usually present with advanced disease making curative attempts difficult Surgery is the only curative therapy since radiotherapy and chemotherapy remain largely ineffective coupled with undesirable side effects Desp ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

    SBC: NEONC TECHNOLOGIES INC            Topic: BT

    DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents

    SBC: Capture Pharmaceuticals, Inc.            Topic: 102

    DESCRIPTION provided by applicant Capture Pharmaceuticals Inc is developing a drug called C E initially intended for treatment of individuals who have been contaminated by radioactive actinide elements following a nuclear terrorism event Because of the similarities between actinides and lanthanides it is expected that C E will also be effective in removing gadolinium Gd a lanthanide in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. High-potency nitro antimicrobials for topical treatment of trichomoniasis

    SBC: DESIGNMEDIX, INC.            Topic: R

    DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Delivery of pathogen trapping antibodies for vaginal protection

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives and an extraordinary economic burden Due to the arsenal of antibiotic resistance mechanisms that these bacteria present traditional antibiotic therapies are often ineffective New strategies that u ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells

    SBC: CELL MICROSYSTEMS INC            Topic: NIAID

    PROJECT SUMMARY Cell Microsystems Inc is an early stage biotechnology company whose mission is the commercialization of a novel cost effective platform enabling the identification and efficient isolation of viable cells based on morphologic and fluorescence signatures as well as characteristics that change over time The CellRaft technology is based on a unique cell array recently developed ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government